CA2984769C - Peptide treatment for inflammation and fibrosis - Google Patents

Peptide treatment for inflammation and fibrosis Download PDF

Info

Publication number
CA2984769C
CA2984769C CA2984769A CA2984769A CA2984769C CA 2984769 C CA2984769 C CA 2984769C CA 2984769 A CA2984769 A CA 2984769A CA 2984769 A CA2984769 A CA 2984769A CA 2984769 C CA2984769 C CA 2984769C
Authority
CA
Canada
Prior art keywords
lys
asp
fibrosis
isolated
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2984769A
Other languages
English (en)
French (fr)
Other versions
CA2984769A1 (en
Inventor
Mario Chojkier
Martina Buck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CA2984769A1 publication Critical patent/CA2984769A1/en
Application granted granted Critical
Publication of CA2984769C publication Critical patent/CA2984769C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA2984769A 2015-05-12 2016-04-11 Peptide treatment for inflammation and fibrosis Active CA2984769C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562160173P 2015-05-12 2015-05-12
US62/160,173 2015-05-12
PCT/US2016/026966 WO2016182660A1 (en) 2015-05-12 2016-04-11 Peptide treatment for inflammation and fibrosis

Publications (2)

Publication Number Publication Date
CA2984769A1 CA2984769A1 (en) 2016-11-17
CA2984769C true CA2984769C (en) 2023-03-21

Family

ID=57248348

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2984769A Active CA2984769C (en) 2015-05-12 2016-04-11 Peptide treatment for inflammation and fibrosis

Country Status (7)

Country Link
US (1) US10434134B2 (https=)
EP (1) EP3294752B1 (https=)
JP (1) JP7372026B2 (https=)
CN (3) CN107531752B (https=)
AU (1) AU2016260190A1 (https=)
CA (1) CA2984769C (https=)
WO (1) WO2016182660A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107531752B (zh) * 2015-05-12 2022-05-10 加利福尼亚大学董事会 用于炎症和纤维化的肽治疗
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
EP3562506A4 (en) * 2016-12-29 2021-01-06 University of Miami METHOD TO MODULATE INFLAMMASOME ACTIVITY AND INFLAMMATION IN THE LUNG
WO2020010273A1 (en) 2018-07-03 2020-01-09 University Of Miami Compositions and methods for treating inflammasome related diseases or conditions
CN113301914B (zh) * 2018-10-25 2026-02-03 尼希尔有限公司 用于治疗和预防纤维化的组合物和方法
CN111770539B (zh) * 2019-04-02 2021-07-09 大唐移动通信设备有限公司 一种lmf选择方法、终端定位服务方法及装置
US20220411500A1 (en) * 2019-11-18 2022-12-29 The Board Of Trustees Of The Leland Stanford Junior University Treatment of fibrosis with combined blockade of il-6 and immune checkpoint
CN114134191B (zh) * 2020-09-04 2023-12-12 琛蓝(美国)营养制品股份有限公司 一种抗炎护肾的蛤蜊肽的制备方法和应用
CN112960780B (zh) * 2021-03-03 2023-02-03 龙江环保集团股份有限公司 一种生物膜载体的预处理方法及生物法污水处理工艺
DE102022203153A1 (de) 2022-03-31 2023-10-05 Psa Automobiles Sa Stauraumanordnung für einen Innenraum eines Fahrzeugs, Fahrzeug mit der Stauraumanordnung und Verfahren zur Benutzung einer Stauraumanordnung
KR102772405B1 (ko) * 2022-06-10 2025-02-26 (주)케어젠 근육 손실 저해 및 근육량 증진 활성을 갖는 펩타이드 및 이의 용도
CN115850440B (zh) * 2022-12-09 2023-07-11 中国人民解放军陆军军医大学 一种长链MyD88诱饵肽及其作为药物的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129349B2 (en) 2000-10-27 2012-03-06 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
AU2002241776A1 (en) * 2000-10-27 2002-06-18 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
WO2003072031A2 (en) * 2002-02-21 2003-09-04 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
US7402567B2 (en) * 2000-10-27 2008-07-22 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
US7119071B2 (en) * 2002-05-21 2006-10-10 University Of Medicine And Dentistry Of New Jersey Amino terminal substance P compositions and methods for using the same
CN101227918A (zh) * 2005-04-29 2008-07-23 加州大学评议会 治疗以炎症反应为特征的病理的肽和肽模拟物
KR20080007491A (ko) * 2005-04-29 2008-01-21 더 리전트 오브 더 유니버시티 오브 캘리포니아 염증성 반응을 특징으로 하는 병리를 치료하기 위한 펩티드및 펩티드 모방체
US8865657B2 (en) * 2005-08-19 2014-10-21 New York University Compositions and methods for inactivating or suppressing inflammatory cells
EP2324048A2 (en) * 2008-07-30 2011-05-25 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof
EP2734220A4 (en) * 2011-07-19 2015-01-21 Thrasos Innovation Inc ANTIFIBROTIC PEPTIDES AND THEIR USE IN METHODS OF TREATING FIBROSIS-CHARACTERIZED DISEASES AND SUFFERING
CN108310396B (zh) * 2012-02-14 2022-07-15 加利福尼亚大学董事会 用于心血管疾病和其它病况的旁分泌基因的全身性递送和受调节的表达
CN107531752B (zh) * 2015-05-12 2022-05-10 加利福尼亚大学董事会 用于炎症和纤维化的肽治疗

Also Published As

Publication number Publication date
CN107531752B (zh) 2022-05-10
CA2984769A1 (en) 2016-11-17
CN114621318A (zh) 2022-06-14
CN114181281A (zh) 2022-03-15
US20180125919A1 (en) 2018-05-10
AU2016260190A1 (en) 2017-11-23
EP3294752B1 (en) 2020-11-04
CN107531752A (zh) 2018-01-02
NZ736840A (en) 2024-05-31
EP3294752A4 (en) 2018-12-19
EP3294752A1 (en) 2018-03-21
JP2018520999A (ja) 2018-08-02
JP7372026B2 (ja) 2023-10-31
US10434134B2 (en) 2019-10-08
WO2016182660A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
CA2984769C (en) Peptide treatment for inflammation and fibrosis
JP6676589B2 (ja) 薬物動態特性の改善されたコンプスタチンアナログ
CN104147591B (zh) Jnk信号转导通路的细胞可渗透性肽抑制剂用于治疗各种疾病的应用
MX2014007799A (es) Peptidos y metodos para usarlos.
US20250018014A1 (en) Method for treating and/or preventing regnase-1-related disease
ES2256070T3 (es) Actividad antimicrobiana de la primera agrupacion cationica de lactoferrina humana.
US20070042962A1 (en) Peptide dependent upregulation of telomerase expression
ES2896919T3 (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (CHC) y otros tipos de cáncer
HK40076050A (en) Peptide treatment for inflammation and fibrosis
CN107406513B (zh) 双链分子(bipartite)及其于治疗异常蛋白聚集的用途
US11547738B2 (en) Compositions and methods for treating fibrosis
DK1781315T3 (en) PEPTIDE INHIBITORS FOR MEDIATION OF stress responses
KR102510514B1 (ko) 세포 살상제
TW202233650A (zh) Masp抑制性化合物及其用途
EP4013442A1 (en) Treatment
WO2022109679A1 (en) Peptides and uses thereof in modulation of amyloid-beta protein degrading proteases
WO2020000061A1 (en) Renal treatment

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210224

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250404

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250404

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260402

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260402